Latest revenue
$156.4M
as of 2026-03-31
Latest net income
$-721.8M
as of 2026-03-31
Net margin
-461.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.11B
- Enterprise value
- $2.11B
- P/E (trailing)
- 8.0×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $11.31
- 52-wk low
- $6.00
- Beta
- —
- Shares out
- 254.2M
5-year trend
About BCRX
Business description and risk factors will appear here once BCRX's latest filing is fully ingested.
Profitability
Operating margin
39.0%
7008.2%Net margin
30.2%
252.9%Return on equity
-221.4%
1285.8%Return on assets
51.3%
383.2%Leverage
Debt / equity
-5.32×
161.8%Long-term debt / equity
-0.01×
98.2%Debt / assets
123.2%
37.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $156.4M | +7.5% | $-721.8M | -2255762.5% | -461.5% |
Q4 2025 2025-12-31 | $406.6M | +209.1% | $245.8M | +1017.5% | 60.5% |
Q3 2025 2025-09-30 | $159.4M | +36.1% | $12.9M | +191.9% | 8.1% |
Q2 2025 2025-06-30 | $163.4M | +49.4% | $5.1M | +140.1% | 3.1% |
Q1 2025 2025-03-31 | $145.5M | +56.9% | $32.0K | +100.1% | 0.0% |
Q4 2024 2024-12-31 | $131.5M | — | $-26.8M | — | -20.4% |
Q3 2024 2024-09-30 | $117.1M | +35.0% | $-14.0M | +61.2% | -12.0% |
Q2 2024 2024-06-30 | $109.3M | +32.5% | $-12.7M | +83.2% | -11.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on BCRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$4.7M
Net activity
−$4.7M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BCRX
Institutional value
$911.5M
Total shares held
99.3M
Distinct holders
166
-105 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 22.7M | $215.6M | +1.5M (+7.2%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11.2M | $107.0M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 11.1M | $106.0M | — | New |
| 4 | abrdn plc | 5.0M | $48.0M | +4.1M (+451.7%) | Added |
| 5 | UBS Group AG | 4.9M | $47.1M | -319.9K (-6.1%) | Trimmed |
| 6 | Nuveen, LLC | 3.8M | $36.4M | +206.9K (+5.7%) | Added |
| 7 | RFG Advisory, LLC | 2.9M | $27.3M | — | New |
| 8 | Fisher Asset Management, LLC | 2.7M | $26.0M | +265.7K (+10.8%) | Added |
| 9 | OP Asset Management Ltd | 2.5M | $25.7M | +2.4M (+1700.0%) | Added |
| 10 | DIMENSIONAL FUND ADVISORS LP | 2.7M | $25.6M | +1.5M (+119.0%) | Added |
| 11 | Candriam S.C.A. | 2.3M | $21.8M | — | New |
| 12 | STIFEL FINANCIAL CORP | 1.8M | $17.4M | +667 (+0.0%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 1.7M | $15.8M | — | New |
| 14 | JPMORGAN CHASE & CO | 1.5M | $14.6M | +698.6K (+82.8%) | Added |
| 15 | Legal & General Group Plc | 1.4M | $13.4M | +1.2M (+568.8%) | Added |
| 16 | Invesco Ltd. | 1.3M | $12.5M | -46.1K (-3.4%) | Trimmed |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 1.3M | $12.4M | -1.2M (-48.8%) | Trimmed |
| 18 | JUPITER ASSET MANAGEMENT LTD | 1.2M | $11.4M | -1.2K (-0.1%) | Trimmed |
| 19 | DEUTSCHE BANK AG\ | 821.4K | $7.8M | +330.3K (+67.3%) | Added |
| 20 | FIRST TRUST ADVISORS LP | 800.9K | $7.6M | +425.9K (+113.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BCRX's latest filing finishes processing.